IMPROVING THE EFFICACY OF CYCLOPHOSPHAMIDE BY USING VERAPAMIL AS A P-GLYCOPROTEIN INHIBITOR IN BREAST CARCINOMA
In women, breast carcinoma is the leading cause of cancer death globally. By the combination of better screening and treatments that moderately improved the survival however much to be done for the women who are refractory to the current therapies. Among Indian females, breast cancer has ranked number one cancer with mortality 12.7 per 100,000 women and age adjusted rate as high as 25.8 per 100,000 women. Statistics reports from various recent national cancer registries were compared for incidence, mortality rates. The age adjusted incidence rate of carcinoma of the breast was found as high as 41 per 100,000 women for Delhi, followed by Chennai (37.9), Bangalore (34.4) and Thiruvananthapuram District (33.7). One of the most common factor for the drug resistance in breast cancer is high expression of P-glycoprotein (P-gp) which is associated with a poor prognosis in patients. Consequently, P-gp represents a potential biomarker of drug resistance. However, a direct role of P-gp as a cause of clinical drug resistance has not been adequately tested in breast cancer. The objective of this study was to evaluate the effect of cyclophosphamide with and without verapamil on P-gp expression. Verapamil was found specific and effective against P-gp expression in breast cancer. In conclusion, treatment efficacy of cyclophosphamide is increased in combination with verapamil against most advanced breast cancer.
Keywords: P-Glycoprotein; Breast Carcinoma; Verapamil; Cyclophosphamide
2. Porter P. Westernizing women’s risk? Breast cancer in lower-income countries. N Engl J Med, 2008; 358:213–216.
3. Monica M Rivera-Franco and Eucario Leon-Rodriguez. Delays in Breast Cancer Detection and Treatment in Developing Countries. Breast Cancer: Basic and Clinical Research, 2018; 12:1-5.
4. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015; 136: E359– 86.
5. Gupta A, Shridhar K, Dhillon PK. A review of breast cancer awareness among women in India: cancer literate or awareness deficit? Eur J Cancer, 2015; 51:2058–66.
6. Porter PL. Global trends in breast cancer incidence and mortality. Salud Publica de ´ Mexico, 2009; 51:s141–s46.
7. Babu GR, Lakshmi SB, Thiyagarajan JA. Epidemiological correlates of breast cancer in South India. Asian Pac J Cancer Prev, 2013; 14:5077–83.
8. Ali I, Wani WA, Saleem K. Cancer scenario in India with future perspectives. Cancer Therapy, 2011; 8:56–70.
9. Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet, 2005; 366:1744–9.
10. Balasubramaniam S, Rotti S, Vivekanandam S. Risk factors of female breast carcinoma: a case control study at Puducherry. Indian J Cancer, 2013; 50:65–70.
11. Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM: Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res, 2013; 15:R92.
12. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D, Soerjomataram I: Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer, 2013.
13. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM: Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014, 74:2913–2921.
14. Colditz GA, Bohlke K: Priorities for the primary prevention of breast cancer. CA Cancer J Clin 2014, 64:186–194.
15. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic in¬teracting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospec¬tive. J Cell Physiol, 2006; 207(3):571–81.
16. Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, et al. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res, 2009; 69(16):6396–404.
17. Liu ZH, He YP, Zhou Y, Zhang P, Qin H. Establishment and identi¬fication of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol Biol Rep, 2011; 38(5):3075–82.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).